Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues.^[4] Iloprost is a prostacyclin mimetic.^[1]

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. (December 2010) This article contains close paraphrasing of non-free copyrighted sources. (February 2024) This article may be in need of reorganization to comply with Wikipedia's layout guidelines. (February 2024) This article may need to be rewritten to comply with Wikipedia's quality standards. (February 2024)

Quick Facts Clinical data, Trade names ...

Iloprost

Clinical data
Trade names	Ventavis, Ilomedine, Aurlumyn
AHFS/Drugs.com	Monograph
MedlinePlus	a612032
License data	US DailyMed: Iloprost
Routes of administration	Inhalation, intravenous
ATC code	B01AC11 (WHO)
Legal status
Legal status	US: ℞-only[1][2] EU: Rx-only[3] In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	Not determined[1]
Protein binding	60%[1]
Metabolism	Via β-oxidation to inactive tetranor-iloprost[1]
Elimination half-life	20–30 minutes[1]
Excretion	Renal (68%) and fecal (12%)[1]
Identifiers
IUPAC name 5-{(E)-(1S,5S,6R,7R)-7-hydroxy-6[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-bicyclo[3.3.0]octan-3-ylidene}pentanoic acid
CAS Number	78919-13-8 Y 73873-87-7
PubChem CID	5311181
DrugBank	DB01088 Y
ChemSpider	4470703 N
UNII	JED5K35YGL
KEGG	D02721 Y
ChEMBL	ChEMBL236025 Y
CompTox Dashboard (EPA)	DTXSID2041046
ECHA InfoCard	100.163.887
Chemical and physical data
Formula	C22H32O4
Molar mass	360.494 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
InChI InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 N Key:HIFJCPQKFCZDDL-ACWOEMLNSA-N N
NY (what is this?)  (verify)

Close

For pulmonary arterial hypertension, iloprost is given via inhalation. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through them. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in the European Union and by Actelion Pharmaceuticals in the US.

In the US, iloprost is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration.^[1]

In the EU, iloprost is indicated for the treatment of people with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.^[3]

In February 2024, the US Food and Drug Administration approved iloprost (Aurlumyn) to treat severe frostbite to reduce the risk of finger or toe amputation.^[2][5]

Iloprost is a synthetic analogue of prostacyclin PGI₂. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer. While Iloprost is an analog of PGI₂ that activates PGI₂'s receptor, the prostacyclin receptor, to stimulate vasodilation, it has little selectivity in that it binds to and activates all four receptors for prostaglandin E2 viz., prostaglandin EP1 receptor, prostaglandin EP2 receptor, prostaglandin EP3 receptor, and prostaglandin EP4 receptor.^[6] Activation of the EP2 and EP4 receptors cause vasodilation but activation of the EP3 receptor causes vasoconstriction.

Contraindications include: unstable angina; within 6 months of myocardial infarction; decompensated cardiac failure (unless under close medical supervision); severe arrhythmias; congenital or acquired heart-valve defects; within 3 months of cerebrovascular events; pulmonary veno-occlusive disease; conditions which increase risk of bleeding.

In clinical studies, common adverse reactions due to inhaled iloprost included: vasodilation (flushing, 27%), cough (39%), headache (30%), flu syndrome (14%), nausea (13%), neck spasms (12%), hypotension (11%), insomnia (8%), and fainting (syncope) (8%); other serious adverse events reported with the use of Ventavis included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, swelling of the limbs (especially around the ankles and feet), and kidney failure.

Serious adverse events reported with the use of inhaled iloprost include congestive heart failure, chest pain, supraventricular tachycardia, shortness of breath, peripheral edema, and kidney failure.